382 related articles for article (PubMed ID: 20150445)
1. Intellectual property. Fixing the legal framework for pharmaceutical research.
Knowles SM
Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
[No Abstract] [Full Text] [Related]
2. Protect pharmaceutical innovation.
Musselwhite LW; Andrews J
Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
[No Abstract] [Full Text] [Related]
3. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
4. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
5. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
Higgins MJ; Graham SJ
Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
[No Abstract] [Full Text] [Related]
6. Science and the law. Working through the patent problem.
Walsh JP; Cohen WM; Arora A
Science; 2003 Feb; 299(5609):1021. PubMed ID: 12586928
[No Abstract] [Full Text] [Related]
7. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
8. An overview of pharmaceutical cocrystals as intellectual property.
Trask AV
Mol Pharm; 2007; 4(3):301-9. PubMed ID: 17477544
[TBL] [Abstract][Full Text] [Related]
9. "Obvious to try": a proper patentability standard in the pharmaceutical arts?
Trask AV
Fordham Law Rev; 2008 Apr; 76(5):2625-68. PubMed ID: 18546581
[No Abstract] [Full Text] [Related]
10. Intellectual property. Drug patents at the Supreme Court.
Hemphill CS; Sampat B
Science; 2013 Mar; 339(6126):1386-7. PubMed ID: 23520096
[No Abstract] [Full Text] [Related]
11. The World Health Organization's prequalification program and its potential effect on data exclusivity laws.
Childs DW
Food Drug Law J; 2005; 60(1):79-97. PubMed ID: 15940855
[No Abstract] [Full Text] [Related]
12. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States.
Miller CP; Ullrich JW
Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591
[TBL] [Abstract][Full Text] [Related]
13. Justices expand rights to experiment with patented drugs.
Pollack A
N Y Times Web; 2005 Jun; ():C1, C8. PubMed ID: 15966121
[No Abstract] [Full Text] [Related]
14. IP litigation in China could drive innovation.
Jia H
Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
[No Abstract] [Full Text] [Related]
15. Surviving the blockbuster syndrome.
Service RF
Science; 2004 Mar; 303(5665):1796-9. PubMed ID: 15031490
[No Abstract] [Full Text] [Related]
16. U.S. patent law. Case probes what's fair game in the search for new drugs.
Kintisch E
Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
[No Abstract] [Full Text] [Related]
17. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
18. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
19. Patents: a threat to innovation?
Manocaran M
Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
[No Abstract] [Full Text] [Related]
20. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
[Next] [New Search]